XML 98 R67.htm IDEA: XBRL DOCUMENT v3.23.1
RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended 28 Months Ended
Dec. 31, 2022
Jan. 31, 2022
Feb. 28, 2021
Nov. 30, 2020
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2020
Dec. 31, 2020
Jun. 30, 2020
Research and development               $ 6,837,133 $ 11,716,718      
License cost               40,000 60,000      
Proceeds from convertible debt $ 3,000,000.0                      
Product sales               4,983,556 5,653,725      
License Revenue [Member]                        
Product sales               632,004      
University of Louisville Research Foundation [Member]                        
Research and development               14,000 243,000      
Yi Xin Zhen Duan Jishu Ltd [Member]                        
Deferred revenue                 670,000      
Product sales                 38,000      
Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member]                        
Product sales                 632,000      
STA Pharmaceutical Co Ltd [Member]                        
Research and development               9,000 3,200,000      
Upfront deposit                     $ 1,100,000  
Sponsored Research and License Agreement [Member]                        
Research and development               164,000 325,000      
License cost               94,000 118,000      
Minimum annual royalties               0 0      
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]                        
Reimbursement of research expenses     $ 2,700,000   $ 693,000              
Agreement term payment, description         In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $              
Regulatory marketing approval, expenses         $ 300,000              
Cumulative sales             $ 500,000,000          
Licensed product net sale         500,000,000              
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]                        
Reimbursement of research expenses                   $ 830,000    
Agreement term payment, description                   In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.    
Research and development               758,000 646,000      
License cost               2,000 28,000      
Proceeds from convertible debt                   $ 50,000    
Patent costs                   200,000    
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]                        
Regulatory marketing approval, expenses             5,000,000          
Cumulative sales         5,000,000              
Regulatory marketing approval, expenses             500,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]                        
Milestone payment         50,000   100,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]                        
Milestone payment         100,000   200,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]                        
Milestone payment         150,000   350,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase Clinical Trial [Member]                        
Milestone payment             500,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                        
Milestone payment         50,000   100,000          
Shortfall payments                   10,000    
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                        
Milestone payment         5,000,000   $ 5,000,000          
Shortfall payments                   $ 50,000    
License Agreement [Member]                        
License cost               338,000 0      
Reimbursement of patent   $ 160,000                    
License Agreement [Member] | Upfront Payment [Member]                        
Reimbursement of patent   $ 150,000                    
License Agreement [Member] | University of Louisville Research Foundation [Member]                        
Upfront license fee                       $ 24,000
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                        
Upfront license fee         20,000              
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                        
Upfront license fee         $ 100,000              
Research and development       $ 430,000                
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member]                        
Cumulative sales           $ 3,000,000            
Licensed product net sale           2,000,000            
License cost               $ 0 $ 2,000      
Proceeds from convertible debt           $ 25,000            
Agreement description           the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate            
Milestone payment for cumulative marketing expenses           $ 100,000            
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] | CE Mark [Member]                        
Cumulative sales           500,000            
Licensed product net sale           3,000,000            
Milestone method revenue recognized           $ 100,000